|
 |
CombiPatchThis page contains recent news articles, when available, and an overview of CombiPatch but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: CombiPatch (when available) Estradiol, the principal intracellular human estrogen, is substantially more active than its metabolites, estrone and estriol, at the cellular level. For the treatment of urogenital symptoms associated with post-menopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria). Mechanism Of Action: Estradiol enters target cells freely (e.g., female organs, breasts, hypothalamus, pituitary) and interacts with a target cell receptor. When the estrogen receptor has bound its ligand it can enter the nucleus of the target cell, and regulate gene transcription which leads to formation of messenger RNA. The mRNA interacts with ribosomes to produce specific proteins that express the effect of estradiol upon the target cell. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. News Articles on Estradiol Noven Pharmaceuticals, Inc. - Medical Equipment - Deals and Alliances Profile ... - Nov 10, 2009 Its key products include Vivelle-Dot, CombiPatch, Estradot, Estalis, Stavzor, Pexeva, Lithobid and Daytrana. The company is The Noven Pharmaceuticals, ... PR-Inside.com (Pressemitteilung) FDA Safety Labeling Changes: CombiPatch, Antidepressants - Mar 23, 2005 March 23, 2005 — The US Food and Drug Administration (FDA) approved in January revisions to safety labeling to advise healthcare professionals of the ... Medscape Noven Announces 2004 Financial Results. - Mar 15, 2005 Novogyne's current quarter net revenues decreased 21% to $24.3 million, reflecting lower sales of CombiPatch due to the continuing effects of the Women's ... Free with registration - Business Wire - AccessMyLibrary.com Business & Finance; Pharmaceutical company announces 8% increase in … - Apr 11, 2005 Novogyne's current quarter net revenues decreased 21% to $24.3 million, reflecting lower sales of CombiPatch due to the continuing effects of the Women's ... Pay-Per-View - Managed Care Weekly Digest - Factiva, from Dow Jones Noven Pharmaceuticals, Inc. Pharmaceutical company announces 8% … - Apr 13, 2005 Novogyne's current quarter net revenues decreased 21% to $24.3 million, reflecting lower sales of CombiPatch due to the continuing effects of the Women's ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Press Release: Launch of an Innovative Way to Learn About Menopause: ... - Apr 10, 2006 Article: Novogyne Pharmaceuticals Acquires CombiPatch from ... ... Vivelle-Dot, Vivelle and CombiPatch ... transdermal system) are marketed by Novogyne ... Pay-Per-View - PR Newswire - HighBeam Research Business & Finance; Pharmaceutical company announces 8% increase in … - Apr 16, 2005 Novogyne's current quarter net revenues decreased 21% to $24.3 million, reflecting lower sales of CombiPatch due to the continuing effects of the Women's ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones ABOUT TARA PARKER-POPE - May 9, 2006 Q: I have used the low-dose Combipatch for years and my gynecologist says it's safe. ... A: Combipatch is a type of hormone treatment used for relief of ... Subscription - Wall Street Journal Online - Dow Jones & Company Press Release: Three Real Women Offer Insight Into Their Hysterectomy... - Jul 14, 2005 Article: Novogyne Pharmaceuticals Acquires CombiPatch from ... PR Newswire; April 2, ... Article: CombiPatch Acquired by Novogyne Pharmaceuticals. ... Pay-Per-View - PR Newswire - HighBeam Research Noven Signs License and Supply Agreements with Procter & Gamble … - Aug 20, 2008 Several commercialized products utilize Noven's DOT Matrix(R) technology, including Vivelle-Dot(R), CombiPatch(R) and Daytrana(R). ... Genetic Engineering News - Genetic Engineering News (press release) More than skin deep: Robert Strauss makes a $125 million investment … - Oct 1, 2007 Those include Vivelle-Dot, an estrogen hormone therapy marketed as Estradot outside the United States; CombiPatch, a combination of estrogen and progestin ... Free with registration - South Florida CEO - AccessMyLibrary.com Erie Times-News : News<br> - Feb 26, 2007 CombiPatch. Esclim. Estraderm. Fempatch. Menostar. Vivelle/Vivelle-Dot. GELS/CREAMS. Estrasorb. EstroGel. VAGINAL CREAMS, PILLS, RINGS. Premarin Cream ... $2.95 - Erie Times-News - NewsBank Inside Futures: Relevant trading-focused information authored by key ... - Oct 19, 2006 CombiPatch is the first combination estrogen/progestin transdermal patch marketed under the brand name Estalis outside the United States. ... Inside Futures Press Release: Boston, MA -- Form4Oracle: Insider Trading Report: … - Nov 26, 2008 CombiPatch, a combination estrogen/progestin transdermal patch marketed under the Estalis brand name outside the United States; Amphetamine Patch, ... Pay-Per-View - M2 Presswire - HighBeam Research Article: WHI results still confusing.(Policy & Practice)(Women's... - Oct 1, 2007 Novogyne manufactures the hormone therapy patches, Vivelle-Dot, Vivelle, and CombiPatch. Read all of this article with a FREE trial ... Pay-Per-View - Family Practice News - HighBeam Research Press Release: Noven Pharmaceuticals Inc - Corporate and Strategic … - Oct 7, 2008 The company markets a portfolio of hormone therapy products including Vivelle Dot, CombiPatch and Daytrana developed using its proprietary transdermal drug ... Pay-Per-View - M2 Presswire - HighBeam Research Popular Brands of Menopause Hormones | Article from AP Online | … - Feb 25, 2007 CombiPatch. Esclim. Estraderm. Fempatch. Menostar. Vivelle/Vivelle-Dot. GELS/CREAMS. Estrasorb. EstroGel. VAGINAL CREAMS, PILLS, RINGS. Premarin Cream ... Pay-Per-View - Associated Press/AP Online - HighBeam Research I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS - Mar 1, 2008 ...category include Prempro, FemHRT, Combipatch and Premphase. Calcitonins. Calcitonin is a hormone that inhibits the bone resorption by oestoclasts and ... $950.00 - GLOBAL INDUSTRY ANALYSTS MARKET OVERVIEW - Alacra Store Associated Press Archive: Glance: Popular brands of menopause … - Feb 25, 2007 CombiPatch. Esclim. Estraderm. Fempatch. Menostar. Vivelle/Vivelle-Dot. GELS/CREAMS. Estrasorb. EstroGel. VAGINAL CREAMS, PILLS, RINGS. Premarin Cream ... $2.95 - Associated Press Archive - NewsBank Q1 2005 Noven Pharmaceuticals Incorporated Earnings Conference Call … - Apr 28, 2005 ...combined prescriptions for Novogyne's products increased 1%, which means Vivelle-Dot's growth more than offset declines in Vivelle and CombiPatch. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com WHI results still confusing.(POLICY & PRACTICE)(Women's Health … - Oct 1, 2007 Novogyne manufactures the hormone therapy patches Vivelle-Dot, Vivelle, and CombiPatch. Read all of this article with a FREE trial ... Pay-Per-View - Internal Medicine News - HighBeam Research Volume: 7.6 million shares, daily average 378,700 shares - Sep 20, 2005 Noven currently sells skin patches that release the hormones estrogen and progestogen under the brand names Vivelle, Vivelle-Dot and CombiPatch. ... Smartmoney.com «The Forbes»: рейтинг брÑ?ндированных препаратов длÑ? ЗГТ на рынке … - Mar 19, 2007 CombiPatch, Esclim, Estraderm, Fempatch, Menostar, Vivelle/Vivelle-Dot; Ñ?реди лекарÑ?твенных Ñ?редÑ?тв в форме гелÑ? или крема — Estrasorb и EstroGel; ... Ð?птека online Noven Reports Second Quarter 2005 Financial Results. - Aug 4, 2005 For the same period, aggregate total prescriptions for Novogyne's products (Vivelle(R), Vivelle-Dot(TM) and CombiPatch(R) combined) increased 6%. ... $4.95 - Business Wire - ECNext Noven reports 3Q 2005 financial results. [4 tables] - Nov 3, 2005 Aggregate total prescriptions for Novogyne's products (Vivelle, Vivelle-Dot and CombiPatch combined) increased 5% for 3Q 2005, while the overall US hormone ... Pay-Per-View - Company Reports - Factiva, from Dow Jones Business & Finance; Pharmaceutical company reports second quarter … - Aug 30, 2005 For the same period, aggregate total prescriptions for Novogyne's products (Vivelle, Vivelle-Dot and CombiPatch combined) increased 6%. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Q2 2005 Noven Pharmaceuticals Incorporated Earnings Conference Call … - Aug 4, 2005 ...these distribution service agreements, are those in place as it relates to Dot and Vivelle and CombiPatch? And who would be the principal negotiator? ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Press Release: New Wireless ID Skin Patch Technology Designed to … - Nov 5, 2007 Article: Novogyne Pharmaceuticals Acquires CombiPatch from Aventis. PR Newswire; April 2, 2001 ; 700+ words ... ... Vivelle and Vivelle-Dot -- Novogyne's ... Pay-Per-View - PR Newswire - HighBeam Research Brand Names/Synonyms: CombiPatch is also known by the following brand names and/or synonyms?-ESTRADIOL; Aerodiol; Agofollin; Alora; Altrad; Amnestrogen; Aquadiol; Bardiol; Beta-Estradiol; Cis-Estradiol; Cis-Oestradiol; Climaderm; Climara; Combipatch; Compudose; Compudose 200; Compudose 365; Corpagen; D-Estradiol; D-Oestradiol; Delestrogen; Depo-Estradiol; Dermestril; Dihydrofollicular Hormone; Dihydrofolliculin; Dihydromenformon; Dihydrotheelin; Dihydroxyesterin; Dihydroxyestrin; Dihydroxyoestrin; Dimenformon; Dimenformon Prolongatum; Diogyn; Diogynets; Divigel; Encore; Esclim; Estinyl; Estrace; Estraderm; Estraderm Tts; Estradiol; Estradiol Cypionate; Estradiol Valerate; Estradiol-17beta; Estradurin; Estraldine; Estrasorb; Estreva; Estrifam; Estring; Estring Vaginal Ring; Estroclim; Estroclim 50; Estrofem 2; Estrofem Forte; Estrogel; Estrogens, Esterified; Estrol; Estrovite; Evex; Evorel; Extrasorb; Femestral; Femestrol; Feminone; Femogen; Fempatch; Femring; Femtrace; Femtran; Follicyclin; Ginedisc; Ginosedol; Gynergon; Gynestrel; Gynodiol; Gynoestryl; Gynpolar; Innofem; Lamdiol; Lynoral; Macrodiol; Macrol; Menest; Menorest; Menostar; Microdiol; NSC-9895; Nordicol; Oestergon; Oestradiol; Oestradiol R; Oestrogel; Oestroglandol; Oestrogynal; Ovahormon; Ovasterol; Ovastevol; Ovociclina; Ovocyclin; Ovocycline; Ovocylin; Perlatanol; Primofol; Profoliol; Profoliol B; Progynon; Progynon Dh; Progynon-Dh; Ricifon; Ritsifon; Sandrena Gel; Sisare Gel; Sk-Estrogens; Soldep; Sotipox; Syndiol; Systen; Theelin, Dihydro-; Tradelia; Trial Sat; Trocosone; Vagifem; Vivelle; Zerella; Zumenon; Ô-Estradiol Drug Category: CombiPatch is categorized under the following by the FDA: Anti-menopausal Agents; Anticholesteremic Agents; Estrogens; ATC:G03CA01; ATC:G03CA03; ATC:L02AA02; ATC:L02AA03 Dosage Forms: DISC (SUSTAINED-RELEASE); GEL; IMPLANT; LIQUID; PATCH; RING (SLOW-RELEASE); SOLUTION; TABLET Absorption: 43% Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |